

Evaluation of COVID-19 vaccination strategies with a delayed second dose

Seyed M. Moghadas,^{1,*†} Thomas N. Vilches,^{2,*} Kevin Zhang,³ Shokoofeh Nourbakhsh,¹ Pratha Sah,⁴ Meagan C. Fitzpatrick,^{4,5} Alison P. Galvani⁴

¹ Agent-Based Modelling Laboratory, York University, Toronto, Ontario, M3J 1P3 Canada

² Institute of Mathematics, Statistics and Scientific Computing, University of Campinas, Campinas SP, Brazil

³ Faculty of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8 Canada

⁴ Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA

⁵ Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W Baltimore St, Baltimore, MD 21201 USA

* These authors contributed equally

† Corresponding author: moghadas@yorku.ca

Abstract

Two of the COVID-19 vaccines currently approved in the United States require two doses, administered three to four weeks apart. Constraints in vaccine supply and distribution capacity, together with a deadly wave of COVID-19 from November 2020 to January 2021 and the emergence of highly contagious SARS-CoV-2 variants, sparked a policy debate on whether to vaccinate more individuals with the first dose of available vaccines and delay the second dose, or to continue with the recommended two-dose series as tested in clinical trials. We developed an agent-based model of COVID-19 transmission to compare the impact of these two vaccination strategies, while varying the temporal waning of vaccine efficacy following the first dose and the level of pre-existing immunity in the population. Our results show that for Moderna vaccines, a delay of at least 9 weeks could maximize vaccination program effectiveness and avert at least an additional 17.3 (95% CrI: 7.8 – 29.7) infections, 0.71 (95% CrI: 0.52 – 0.97) hospitalizations, and 0.34 (95% CrI: 0.25 – 0.44) deaths per 10,000 population compared to the recommended 4-week interval between the two doses. Pfizer-BioNTech vaccines also averted an additional 0.61 (95% CrI: 0.37 – 0.89) hospitalizations and 0.31 (95% CrI: 0.23 – 0.45) deaths per 10,000 population in a 9-week delayed second dose strategy compared to the 3-week recommended schedule between doses. However, there was no clear advantage of delaying the second dose with Pfizer-BioNTech vaccines in reducing infections, unless the efficacy of the first dose did

not wane over time. Our findings underscore the importance of quantifying the characteristics and durability of vaccine-induced protection after the first dose in order to determine the optimal time interval between the two doses.

Introduction

The spread of coronavirus disease 2019 (COVID-19) has ravaged global health and suppressed economic activity despite the range of mitigation measures implemented by countries worldwide [1]. A number of vaccines, including those developed by Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca, have received emergency use authorization from regulatory bodies in different countries [2]. Clinical trials and evaluations of mass vaccination campaigns have demonstrated that these vaccines can provide high levels of protection against symptomatic and severe disease with two doses administered three to four weeks apart [3–6]. In contrast to the remarkable speed of development, vaccine delivery has proven to be challenging due to supply shortages and limited distribution capacity in several countries [7,8].

The emergence of novel, more contagious SARS-CoV-2 variants in several countries [9–13], and the potential for their widespread transmission have led to a public health conundrum regarding whether to vaccinate more individuals with the first dose of available vaccines and delay the second dose, or to prioritize completion of the two-dose series based on tested schedules in clinical trials [14–17]. Broader population-level protection against COVID-19 in a delayed second dose (DSD) strategy, even with lower individual-level efficacy from the first dose in the short term, may improve the impact of vaccination compared to the recommended two-dose strategy that provides more complete protection to a smaller subset of the population [14,17]. However, the conditions under which this improvement is achievable remain unexamined [18], such as the durability of first-dose efficacy and protection against infection [19–21].

Here, we employed an agent-based model of COVID-19 transmission and vaccination to compare the epidemiological impact of tested and DSD vaccination schedules, considering a range of pre-existing immunity accrued since the emergence of COVID-19. We determined the optimal timing for administering the second dose based on vaccine efficacy estimated in clinical trials and population-level studies following first and second doses [3,4,6,22–24]. For Moderna's two-dose vaccine, we show that a DSD strategy would outperform the recommended interval between doses in terms of reducing the number of hospitalizations and deaths. The maximum benefits would be achieved with a delay of at least 9 weeks from the recommended schedule for administering the second dose. A DSD strategy with Pfizer-BioNTech vaccines is comparatively inferior to Moderna vaccines, and the delay to achieve maximum benefits depends on the durability of the first-dose efficacy.

Methods

Model structure

We extended our previous model of agent-based COVID-19 transmission to include vaccination [25]. The model encapsulates the natural history of COVID-19 with classes of individuals including: susceptible; vaccinated; latently infected (not yet infectious); asymptomatic (and infectious); pre-symptomatic (and infectious); symptomatic with either mild or severe illness; recovered; and dead. Model population was stratified into six age groups of 0-4, 5-19, 20-49, 50-64, 65-79, and 80+ years based on United States (US) census data [26]. We sampled daily contacts within and between age groups from a negative-binomial distribution parameterized using an empirically-determined contact network (Appendix, Table A1) [27].

Disease dynamics

In our agent-based model, the risk of infection for people susceptible to COVID-19 depended on contact with infectious individuals that could be in asymptomatic, pre-symptomatic, or symptomatic stages of the disease. Using recent estimates, we parameterized the infectivity of asymptomatic, mild symptomatic, and severe symptomatic individuals to be 26%, 44%, and 89% relative to the pre-symptomatic stage [28–30]. For each infected individual, the incubation period was sampled from a Gamma distribution with a mean of 5.2 days [31]. A proportion of infected individuals developed symptomatic disease following a pre-symptomatic stage. The duration of the pre-symptomatic stage and infectious period following symptom onset was sampled from a Gamma distribution with a mean of 2.3 days and 3.2 days, respectively [29,32,33]. Those who did not develop symptomatic disease remained asymptomatic until recovery, with an infectious period that was sampled from a Gamma distribution with a mean of 5 days [33,34]. We assumed that recovered individuals are immune against reinfection for the remainder of simulation timelines. Model parameters are summarized in Appendix, Table A2.

Infection outcomes

A proportion of severe symptomatic cases were hospitalized within 2-5 days of symptom onset [25,35], and thereafter did not contribute to the spread of infection. We assumed that all mild symptomatic cases and severely ill individuals self-isolated within 24 hours of symptom onset. The daily number of contacts during self-isolation was reduced by an average of 74%, based on a matrix derived from a representative sample population during COVID-19 lockdown [36]. Non-ICU and ICU admissions were parameterized based on age-stratified data for COVID-19 hospitalizations, and the presence of comorbidities [37,38]. The lengths of non-ICU and ICU stays were sampled from Gamma distributions with means of 12.4 and 14.4 days, respectively [39,40].

Vaccination

We implemented a two-dose vaccination campaign, and simulated a rollout strategy with a daily rate of 30 vaccine doses per 10,000 population, corresponding to 1 million vaccine doses per day for the entire US population. This rate corresponds to the goal of administering ~100 million vaccine doses in the first 100 days, as outlined by the Biden administration [33]. As an additional scenario, we extended our analysis to a daily vaccination rate of 45 doses per 10,000 population, corresponding to 1.5 million daily doses in the US. In all scenarios, prioritization was sequentially set to: (i) healthcare workers (5% of the total population) [41], adults with comorbidities, and those aged 65 and older; and (ii) other individuals aged 18-64 [42]. We assumed that the maximum achievable coverage was 95% among healthcare workers and those aged 65 and older. This maximum coverage was set to 70% among other age groups, with an age-dependent distribution (Appendix, Table A3).

For Moderna vaccines, the interval between the first and second doses in the recommended schedule (i.e., tested in clinical trials) was 28 days [3]. This interval was 21 days for Pfizer-BioNTech vaccines [4]. Vaccine coverage of the entire population with two doses under the recommended schedules reached 51% and 76% for Moderna, and 52% and 77% for Pfizer-BioNTech with vaccination rates of 30 and 45 doses per day, respectively, within one year.

We performed a review of published studies and the US Food and Drug Administration (FDA) briefing documents on the efficacy of Moderna and Pfizer-BioNTech vaccines in preventing infection, symptomatic disease, and severe disease [3,4,6,22–24]. We extracted reported estimates for vaccine efficacies and associated timelines, as presented in Figure 1. These estimates indicate no statistically significant difference between the protection of vaccinated and unvaccinated cohorts for the first 10-14 days following the first dose of vaccines.




Figure 1. Efficacy of Moderna and Pfizer-BioNTech vaccines against all infection, symptomatic disease and severe disease, derived from published studies and US FDA briefing documents [3,4,6,22–24]. (*) During the first 14 days following the first dose of vaccines, there was no statistically significant difference between the protection in the vaccinated and unvaccinated cohorts. (#) Conservatively assumed to be the same as efficacy against infection during the preceding 14 days (prior to the second dose). (†) Conservatively assumed to be the same as efficacy against severe disease during the preceding 14 days (prior to the second dose). (§) Assumed to be the same as efficacy against symptomatic COVID-19.

In order to evaluate the impact of vaccination with DSD relative to the tested schedules in clinical trials, in the base-case scenario, we assumed that the efficacy of the first dose for both Moderna and Pfizer-BioNTech vaccines would be maintained for up to 18 weeks without a second dose. As a sensitivity analysis, we considered a waning rate of 5% per week for first-dose vaccine efficacy starting from week 7 after the first dose. We assumed that the full two-dose efficacy was achieved regardless of delay in the administration of the second dose from the recommended schedule [43]. We simulated the model with the mean, lower bound, and upper bound of the 95% CIs for vaccine efficacy of the first and second doses against infection, symptomatic disease, and severe disease.

Model scenarios

We considered a range of 10%-30% pre-existing immunity (i.e., seropositivity prior to vaccination) in the population, with 20% for the base-case scenario [44,45]. To parameterize the model at a given level of pre-existing immunity, we ran simulations in the absence of vaccination, and derived the infection rates in different age groups once the overall attack rate reached the pre-specified level. The corresponding age distributions of recovered (i.e., immune against reinfection) individuals were used for the initial population at the start of vaccination. We simulated the model with a 10,000 population for a time horizon of one year to evaluate the impact of DSD vaccination compared with the recommended schedule of 28-day interval for Moderna vaccines and 21-day interval for Pfizer-BioNTech vaccines. For the results presented here, outcomes of infections, hospitalizations, and deaths were averaged over 1000 independent replications of each scenario. Credible intervals (CrI) at the 5% significance level were generated using the bias-corrected and accelerated bootstrap method (with 500 replications).

Results

DSD vaccination without waning efficacy of the first dose

When the efficacy of the first dose did not wane for up to 18 weeks after being administered, we found that the DSD strategy with the daily rate of 30 vaccine doses per 10,000 population averted more infections, hospitalizations, and deaths, compared to the recommended schedules for both Moderna and Pfizer-BioNTech vaccines (Figure 2). The largest reduction of severe outcomes was achieved with a 12-15 week delay in administering the second dose. At 20% pre-existing immunity, for example, a 12-week DSD strategy with mean efficacy of Moderna vaccines would avert an additional 0.85 (95% CrI: 0.62 - 1.07) hospitalizations and 0.41 (95% CrI: 0.33 - 0.52) deaths per 10,000 population, compared to the recommended vaccination schedule (Figure 2B-2C). We observed similar benefits of a DSD strategy for Pfizer-BioNTech vaccines, averting 0.74 (95% CrI: 0.48 - 1.04) hospitalizations and 0.41 (95% CrI: 0.31 - 0.54) deaths per 10,000 population in a 12-week delay scenario. As the daily number of vaccine doses increases, the maximum benefits of a DSD strategy in averting hospitalizations and deaths would be achieved with a shorter delay in administering the second dose (Figure 2E-2F).

When simulating the model with upper bounds of vaccine efficacy, we found that the benefits of a DSD strategy in terms of reducing infections, hospitalizations, and deaths were comparable to those obtained in scenarios with mean efficacy for both Moderna and Pfizer-BioNTech vaccines (Appendix, Figure A1). However, when vaccine efficacy was at the lower bounds of estimated ranges, there was no clear advantage with a DSD strategy compared to the recommended schedules in terms of reducing infections (Appendix, Figure A2). While both vaccines averted more hospitalizations and deaths in a DSD strategy, Moderna vaccines outperformed Pfizer-BioNTech vaccines in all scenarios of pre-existing immunity at the lower bounds of vaccine efficacy. The largest reduction of severe outcomes was achieved with a 9-15 week delay in the second dose (Appendix, Figure A2). These benefits are due to the prioritization of elderly and

individuals with comorbidities receiving the first dose; thus, increasing their vaccine coverage and reducing severe outcomes among these high-risk individuals.




Figure 2. Projected number of infections, hospitalizations, and deaths averted per 10,000 population in a DSD vaccination program compared to the recommended schedule of two-doses of Moderna (with a 28-day interval) and Pfizer-BioNTech (with a 21-day interval) vaccines. The daily vaccination rate was (A,B,C) 30 doses and (D,E,F) 45 doses per 10,000 population. Vaccine efficacy was set to the mean of estimated ranges (Figure 1) without waning of the first-dose efficacy prior to the administration of the second dose.

DSD vaccination with waning efficacy of the first dose

We found that Moderna vaccines in a DSD strategy averted more infections compared to the recommended schedule of 28 days between doses (Figure 3). However, there was no advantage of DSD using Pfizer-BioNTech vaccines in reducing infections. Both vaccines averted more hospitalizations and deaths with DSD. The largest reduction of hospitalizations and deaths using Moderna vaccines was still achieved with a 12-15 week delay in administering the second dose. With Pfizer-BioNTech vaccines, the highest benefits in reducing the same outcomes would be attained with a shorter delay of 6-12 weeks in a DSD strategy. Overall, Moderna vaccines outperformed Pfizer-BioNTech vaccines with regards to achieving the maximum benefits with a DSD strategy. For example, with 20% pre-existing immunity and a daily vaccination rate of 30 doses, Moderna vaccines averted an additional 0.72 (95% CrI: 0.54 - 0.96) hospitalizations per 10,000 population with a 12-week DSD strategy (Figure 3B). For Pfizer-BioNTech vaccines, this maximum benefit was achieved with a 9-week DSD which averted 0.44 (95% CrI: 0.16 - 0.72) hospitalizations. Similarly, we projected that Moderna and Pfizer-BioNTech vaccines would avert an additional 0.39 (95% CrI: 0.29 - 0.49) and 0.26 (95% CrI: 0.16 - 0.39) deaths per 10,000 population with a 12-week delay of administering the second dose, respectively (Figure 3C).

When the daily vaccination rate increased to 45 doses, we observed similar outcomes of a DSD strategy with Moderna vaccines outperforming Pfizer-BioNTech vaccines in the corresponding scenarios (Figure 3D-3F). The largest benefits of Moderna vaccines in terms of averting hospitalizations and deaths were achieved with a shorter delay of 9-12 weeks in administering the second dose, but still outperformed those obtained using Pfizer-BioNTech vaccines in all scenarios of pre-existing immunity (Figure 3E,3F).

When simulating the model with upper bounds of vaccine efficacy with waning, we found that the performance of a DSD strategy in terms of reducing infections, hospitalizations, and deaths was qualitatively similar to those obtained in scenarios with mean efficacy for both Moderna and Pfizer-BioNTech vaccines (Appendix, Figure A5). However, when vaccine efficacy was at the lower bounds of estimated ranges, the impact of a DSD strategy was reduced significantly in both vaccines (Appendix, Figure A6). There was no advantage in reducing infections with DSD compared to the recommended schedules. We found that, while the performance of a DSD strategy in averting hospitalization and deaths depends on the level of pre-existing immunity, Moderna vaccines still outperformed Pfizer-BioNTech vaccines in most scenarios of pre-existing immunity with a delay of longer than 6 weeks from the recommended schedules (Appendix, Figure A6).




Figure 3. Projected number of infections, hospitalizations, and deaths averted per 10,000 population in a DSD vaccination program compared to the recommended schedule of two-doses of Moderna (with a 28-day interval) and Pfizer-BioNTech (with a 21-day interval) vaccines. The daily vaccination rate was (A,B,C) 30 doses and (D,E,F) 45 doses per 10,000 population. Vaccine efficacy was set to the mean of estimated ranges (Figure 1), and the waning rate of first-dose efficacy was 5% per week, starting from week 7 after the first dose prior to the administration of the second dose.

Discussion

Vaccination can have a substantial impact on mitigating COVID-19 outbreaks [46]. However, vaccine distribution in the US did not meet the initial goal set by federal officials due to

significant shortfalls in distribution [47]. Challenges with vaccine supply and rollout, coupled with a deadly wave of outbreaks that overwhelmed hospitals [48–50], and the emergence of highly transmissible SARS-CoV-2 variants [12,51,52], sparked a debate as to whether available vaccines should be used to rapidly increase the coverage with the first dose [14–17], or be distributed according to tested schedules. While the US has committed to delivering the second dose on time for those who receive the first dose [53], a few countries have approved guidelines for DSD, including UK and Canada to defer the second dose by up to 12 and 16 weeks, respectively [54,55].

In this study, we evaluated whether deferral of the second dose beyond the recommended schedules of 3 and 4 weeks for Pfizer-BioNTech and Moderna vaccines, respectively, could improve the effectiveness of vaccination programs in reducing infections, hospitalizations, and deaths. We found that if the efficacy of the first dose did not wane until the administration of the second dose, then the DSD strategy will be more effective than the recommended schedules for both Pfizer-BioNTech and Moderna vaccines, achieving maximum benefits with a delay of 12–15 weeks. If the efficacy of the first dose wanes over time, our results show that delaying the second dose of Moderna vaccines could prevent more infections, hospitalizations, and deaths compared to the recommended 4-week interval between the two doses. The maximum benefits for averting severe outcomes were achieved with a DSD of 9–15 weeks. A DSD strategy with Pfizer-BioNTech vaccines beyond the 3-week tested schedule, on the other hand, may lead to a higher number of infections compared to the recommended schedule, if the first-dose efficacy waned over time. However, depending on the level of pre-existing immunity, additional hospitalizations and deaths could be averted with DSD as a result of vaccine prioritization for individuals at higher risk of severe outcomes. While our study aimed to compare the outcomes of vaccination between the recommended schedules and DSD, we note that the reduction in disease burden by DSD strategy would be even higher when compared to a scenario of no vaccination.

Our results are based on available evidence and estimated vaccine efficacy in published studies of clinical trials, FDA briefing documents, and vaccination campaigns [3,4,6,22–24]. Key data on the durability of vaccine-induced immunity following the first (if the second dose is delayed) and second doses, and the rate of temporal decline of immunity post-vaccination are still lacking. Our model assumptions were conservative and based on limited empirical evidence available thus far. For example, in the base-case scenario, we assumed that the estimated protection efficacy of vaccines against infection and symptomatic/severe disease remained intact until the administration of the second dose. Further, we assumed that the protection efficacies after two doses in a DSD strategy will be the same as those estimated with two doses in schedules tested in clinical trials. As sensitivity analyses, we also considered scenarios in which vaccine efficacy of the first dose waned over time when the second dose was delayed. Currently, there are no data that quantify the decline of vaccine-induced immunity under different schedules of a DSD strategy. However, as clinical investigations on vaccine performance continue and more

estimates on population-wide effectiveness of vaccination campaigns become available, our assumptions may need to be revised. Should any future evidence alter these assumptions, further analyses would be warranted and conclusions of our study might change.

Our findings highlight two important parameters in the evaluation of vaccination programs with DSD. First and foremost is the durability of vaccine efficacy [20,21], which requires clinical and epidemiological studies monitoring vaccinated individuals for several weeks after inoculation with the first dose. Second is the ability of vaccines to block transmission. In addition to these parameters, vaccine supply and many other factors such as the potential for the emergence of vaccine-resistant strains under low individual-level protection; public confidence in vaccines; risk behaviour of individuals following vaccination; and the possibility of a drop in uptake of the second dose with a delay significantly longer than the recommended schedules, would be important considerations in public health decision-making regarding DSD vaccination [19]. However, given the relatively high vaccine efficacies estimated after the first dose against severe outcomes (i.e., over 50% in most end-points), broader population-level protection would be expected to further reduce the disease burden, even with limited vaccine supplies in the near term. When racing against a burgeoning outbreak, our results show that prioritizing vaccine coverage with rapid distribution of the first dose would be critical to mitigating adverse outcomes and allow the healthcare system to also address non-COVID-19 medical needs of the population. In the case of low incidence, it would still be important to accelerate vaccination with the first dose to protect the maximum number of individuals ahead of any outbreak surge.

Funding. Canadian Institutes of Health Research [OV4 – 170643, COVID-19 Rapid Research]; São Paulo Research Foundation [18/24811-1]; the National Institutes of Health [1R01AI151176-02S1; 1K01AI141576-01], and the National Science Foundation [RAPID 2027755; CCF-1918784].

Conflict of Interest. The authors declare that they have no conflict of interest.

Reproducibility Statement. The computational system and parameters are available under an open-source license at: https://github.com/thomasvilches/delayed_dose.

References

1. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. *Int J Surg Lond Engl*. 2020;78: 185–193. doi:10.1016/j.ijssu.2020.04.018
2. The New York Times. Coronavirus Vaccine Tracker. Available: <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>

3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383: 2603–2615. doi:10.1056/NEJMoa2034577
4. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2020; NEJMoa2035389. doi:10.1056/NEJMoa2035389
5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet*. 2021;397: 99–111. doi:10.1016/S0140-6736(20)32661-1
6. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med*. 2021; NEJMoa2101765. doi:10.1056/NEJMoa2101765
7. The Economist. Rich countries grab half of projected covid-19 vaccine supply. 2020. Available: <https://www.economist.com/graphic-detail/2020/11/12/rich-countries-grab-half-of-projected-covid-19-vaccine-supply>
8. SupplyChain247. The Complex Logistical Challenges of Vaccine Distribution. Jan 2021. Available: https://www.supplychain247.com/article/the_complex_logistical_challenges_of_vaccine_distribution
9. Mahase E. Covid-19: What new variants are emerging and how are they being investigated? *BMJ*. 2021; n158. doi:10.1136/bmj.n158
10. van Oosterhout C, Hall N, Ly H, Tyler KM. COVID-19 evolution during the pandemic – Implications of new SARS-CoV-2 variants on disease control and public health policies. *Virulence*. 2021;12: 507–508. doi:10.1080/21505594.2021.1877066
11. Centers for Disease Control and Prevention. Emerging SARS-CoV-2 Variants. 2021. doi:<https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html>
12. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. 2021 [cited 9 Jan 2021]. doi:10.1101/2020.12.30.20249034
13. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 2021; eabg3055. doi:10.1126/science.abg3055
14. Tuite AR, Zhu L, Fisman DN, Salomon JA. Alternative Dose Allocation Strategies to Increase Benefits From Constrained COVID-19 Vaccine Supply. *Ann Intern Med*. 2021; M20-8137. doi:10.7326/M20-8137
15. Barnabas RV, Wald A. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose. *Ann Intern Med*. 2021; M20-8060. doi:10.7326/M20-8060

16. Paltiel AD, Zheng A, Schwartz JL. Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment. *Ann Intern Med.* 2021; M20-7866. doi:10.7326/M20-7866
17. Matrajt L, Eaton J, Leung T, Dimitrov D, Schiffer JT, Swan DA, et al. Optimizing vaccine allocation for COVID-19 vaccines: critical role of single-dose vaccination. 2021 [cited 17 Jan 2021]. doi:10.1101/2020.12.31.20249099
18. Bieniasz P. The case against delaying SARS-CoV-2 mRNA vaccine boosting doses. *Clin Infect Dis.* 2021; ciab070. doi:10.1093/cid/ciab070
19. John P. Moore. How do you take your vaccine—one lump or two? 2021. Available: <https://blogs.bmj.com/bmj/2021/01/06/john-p-moore-how-do-you-take-your-vaccine-one-lump-or-two/>
20. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J Med.* 2021;384: 80–82. doi:10.1056/NEJMc2032195
21. Sewell HF, Robertson JF, Stewart M, Kendrick D, Bird SM. Revisiting the UK’s strategy for delaying the second dose of the Pfizer covid-19 vaccine. 2021. Available: <https://blogs.bmj.com/bmj/2021/01/20/revisiting-the-uks-strategy-for-delaying-the-second-dose-of-the-pfizer-covid-19-vaccine/>
22. U.S. Food and Drug Administration. Moderna COVID-19 Vaccine VRBPAC Briefing Document. 2020 Dec. Available: <https://www.fda.gov/media/144434/download>
23. U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine VRBPAC Briefing Document. 2020 Dec. Available: <https://www.fda.gov/media/144246/download>
24. Lipsitch M, Kahn R. Interpreting vaccine efficacy trial results for infection and transmission. *Epidemiology*; 2021 Feb. doi:10.1101/2021.02.25.21252415
25. Shoukat A, Wells CR, Langley JM, Singer BH, Galvani AP, Moghadas SM. Projecting demand for critical care beds during COVID-19 outbreaks in Canada. *CMAJ Can Med Assoc J J Assoc Medicale Can.* 2020;192: E489–E496. doi:10.1503/cmaj.200457
26. U.S. Census Bureau QuickFacts U.S. Census Bureau QuickFacts. United States. Population Demographics. 2020. Available: <https://www.census.gov/quickfacts/fact/table/US/PST045219>
27. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. Riley S, editor. *PLoS Med.* 2008;5: e74. doi:10.1371/journal.pmed.0050074
28. Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science.* 2020;368: eabb6936. doi:10.1126/science.abb6936
29. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The implications of silent transmission for the control of COVID-19 outbreaks. *Proc Natl Acad Sci.* 2020;117: 17513–17515. doi:10.1073/pnas.2008373117
30. Sayamanathan AA, Heng CS, Pin PH, Pang J, Leong TY, Lee VJ. Infectivity of

- asymptomatic versus symptomatic COVID-19. *The Lancet*. 2021;397: 93–94.
doi:10.1016/S0140-6736(20)32651-9
31. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020;382: 1199–1207. doi:10.1056/NEJMoa2001316
 32. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*. 2020;26: 672–675.
doi:10.1038/s41591-020-0869-5
 33. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science*. 2020;368: 489–493. doi:10.1126/science.abb3221
 34. Gatto M, Bertuzzo E, Mari L, Miccoli S, Carraro L, Casagrandi R, et al. Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures. *Proc Natl Acad Sci*. 2020;117: 10484–10491. doi:10.1073/pnas.2004978117
 35. Moghadas SM, Shoukat A, Fitzpatrick MC, Wells CR, Sah P, Pandey A, et al. Projecting hospital utilization during the COVID-19 outbreaks in the United States. *Proc Natl Acad Sci U S A*. 2020;117: 9122–9126. doi:10.1073/pnas.2004064117
 36. CMMID COVID-19 working group, Jarvis CI, Van Zandvoort K, Gimma A, Prem K, Klepac P, et al. Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. *BMC Med*. 2020;18: 124. doi:10.1186/s12916-020-01597-8
 37. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69: 458–464. doi:10.15585/mmwr.mm6915e3
 38. CDC COVID-19 Response Team, CDC COVID-19 Response Team, Chow N, Fleming-Dutra K, Gierke R, Hall A, et al. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69: 382–386. doi:10.15585/mmwr.mm6913e2
 39. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020;8: 475–481.
doi:10.1016/S2213-2600(20)30079-5
 40. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*. 2020;26: 1470–1477. doi:10.3201/eid2607.200282
 41. U.S. Bureau of Labor Statistics. Number of hospitals and hospital employment in each state in 2019: The Economics Daily. Available: <https://www.bls.gov/opub/ted/2020/number-of-hospitals-and-hospital-employment-in-eachstate-in-2019.htm>
 42. Committee on Equitable Allocation of Vaccine for the Novel Coronavirus, National

- Academy of Medicine, National Academies of Sciences, Engineering, and Medicine. Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine. Washington, D.C.: National Academies Press; 2020. p. 25914. doi:10.17226/25914
43. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet*. 2021;397: 881–891. doi:10.1016/S0140-6736(21)00432-3
 44. SeroTracker. COVID-19 Seroprevalence. 2020 Dec. Available: <https://serotracker.com/Dashboard>
 45. CDC COVID Data Tracker. United States COVID-19 Seroprevalence Estimate by States. Available: <https://covid.cdc.gov/covid-data-tracker/#national-lab>
 46. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv; 2020 Nov. doi:10.1101/2020.11.27.20240051
 47. NPR News. U.S. Likely Will Miss Goal Of Vaccinating 20 Million By The New Year. 31 Dec 2020. Available: <https://www.npr.org/sections/coronavirus-live-updates/2020/12/31/952208601/u-s-likely-will-miss-goal-of-vaccinating-20-million-by-the-new-year>
 48. The Globe And Mail. Hospitals risk being overwhelmed because of holiday COVID-19 rule-breakers. 4 Jan 2021. Available: <https://www.theglobeandmail.com/canada/article-hospitals-risk-being-swamped-because-of-holiday-rule-breakers/>
 49. CTV News. Overwhelmed, California hospitals contemplate rationing care. 19 Dec 2020. Available: <https://www.ctvnews.ca/health/coronavirus/overwhelmed-california-hospitals-contemplate-rationing-care-1.5238887>
 50. CIDRAP. COVID-19 overwhelming hospitals, morgues in US, other nations. 10 Dec 2020. Available: <https://www.cidrap.umn.edu/news-perspective/2020/12/covid-19-overwhelming-hospitals-morgues-us-other-nations>
 51. Centre for Mathematical Modelling of Infectious Diseases London School of Hygiene and Tropical Medicine. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. Available: https://cmmid.github.io/topics/covid19/reports/uk-novel-variant/2020_12_23_Transmissibility_and_severity_of_VOC_202012_01_in_England.pdf
 52. Mahase E. Covid-19: What new variants are emerging and how are they being investigated? *BMJ*. 2021; n158. doi:10.1136/bmj.n158
 53. The Washington Post. U.S. health officials say they plan to stick with two-dose coronavirus regimen. 4 Jan 2021. Available: <https://www.washingtonpost.com/health/2021/01/04/covid-vaccine-one-shot/>
 54. Global News. Canada can delay 2nd coronavirus vaccine dose if there's a shortage, panel

- says. 13 Jan 2021. Available: <https://globalnews.ca/news/7573376/coronavirus-vaccine-2nd-dose-delay/>
55. The Guardian. Covid-19 second-stage vaccinations to be delayed across UK. 30 Dec 2020. Available: <https://www.theguardian.com/world/2020/dec/30/covid-19-second-stage-nhs-vaccinations-delayed-across-uk>
 56. Systrom K, Vladek T, Krieger M. Rt.live. GitHub repository. 2020. Available: <https://github.com/rtcovidlive/covid-model>. Accessed 16 Nov 2020.
 57. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2020;25. doi:10.2807/1560-7917.ES.2020.25.10.2000180
 58. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis.* 2020;94: 154–155. doi:10.1016/j.ijid.2020.03.020
 59. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69: 377–381. doi:10.15585/mmwr.mm6913e1